Category: Clinician Articles


This month Enzymotec, the makers of Vayarin, quietly announced on their website that they would no longer sell its product in the U.S. This leaves patients who have been taking it in a quandary without support. While the company’s announcement cites “a lack of alignment with our business strategy” as an explanation, no one ... Read More
March 26, 2019David W. Goodman, MD


Faraone SV, Silverstein MJ, Antshel K, Biederman J, Goodman DW, Mason O, Nierenberg AA, Rostain A, Stein MA, Adler LA.  J of Attention Disorder 2018:1-16 click to read abstract
June 7, 2018RoseMarie AddAdult


This is Part 2 to a previous blog: This brings us to the next objection insurance companies will raise – the issue of safety. In citing safety as a reason for the denial of daily stimulant doses that exceed FDA daily max allowances, they deliberately and knowingly misrepresent the meaning of ... Read More


National Public Radio recently posted my interview (click on "Heard on Morning Editon") from April 2017 about a research publication reviewing a revised adult ADHD screener developed in coordination with the World Health Organization. What the journalist didn't know at the time that I will share with you is that I ... Read More


American Professional Society for ADHD and Related Disorders has posted videos by many of the speakers at this year's conference. For those professionals and others who are interested in the covered topics, we can listen the 5 min videos descriptions by the speakers of their topics. My video about ADHD ... Read More
December 29, 2015David W. Goodman, MD


On December 16, 2015, our article reviewing the world’s English scientific literature on ADHD in adults over age 50 years was published online in Drugs and Aging, an international journal. While there is a paucity of research, there are enough publications to merit pulling this literature together into one paper. ... Read More
December 22, 2015David W. Goodman, MD


Over the years, it has been challenging for psychiatrists to manage the risks of psychiatric medications in patients who considered childbearing, become pregnant, and chose to breastfeed. And while there is some information on many psychiatric medications, there remains little in regards to stimulant medications. Unfortunately, there is no registry ... Read More
December 8, 2014David W. Goodman, MD


With an increasing number of adults being nearly diagnosed with ADHD, the expense of ADHD medications for insurance companies has escalated. While the annual prescription increase for childhood ADHD is less than 3%, the ADHD prescription market is growing at approximately 10% per year. As a result of this change, ... Read More
September 10, 2014David W. Goodman, MD


Step therapy is the requirement that a patient first try less costly medication before being prescribed medication a doctor thinks is best for the individual patient and specific symptoms/history. In the recent past, insurance companies had requested that adults with ADHD first be treated with a short-acting stimulant despite the ... Read More


The following post from the FDA appeared today about complaints that generic long-acting methylphenidates (brand name-Concerta) may not work equally well. "In the case of the ADHD drug — certain generic versions of methylphenidate hydrochloride  (Concerta, Janssen Pharmaceuticals) — the issue is a possible lack of therapeutic effect, which may be ... Read More
April 22, 2014David W. Goodman, MD